Table 1.
Patient characteristics
| Study number | Sex/age, y | Rai stage | IGHV gene, % germline | ZAP-70 IHC | CD38, % | FISH | BM, % cellular/pattern | LN-pc pattern | TTT, mo |
|---|---|---|---|---|---|---|---|---|---|
| C01 | F/61 | 2 | 4-59, 100 | + | 28 | +12 | 75/D | prominent | +28.5 |
| C02 | F/60 | 1 | 3-21, 96.3 | + | 88 | 11q−, 13q− | 85/D+N | typical | +79.7 |
| C03 | M/60 | 1 | 1-18, 93.9 | − | 0 | 13q− | 90/D | prominent | 106.4 |
| C04 | M/51 | 3 | 3-33, 100 | + | 53 | 11q− | 90/D | typical | +3.5 |
| C05 | M/57 | 4 | 3-15, 97.7 | − | 46 | 11q−, 13q− | na | typical | +221 |
| C06 | M/58 | 3 | 3-30, 100 | + | 60 | normal | na | prominent | +9.6 |
| C07 | F/61 | 2 | 3-21, 100 | + | 81 | normal | na | typical | +21.6 |
| C08 | M/59 | 1 | 3-09, 99.3 | + | 47 | 11q−, 13q− | 50/D+N | typical | +11.6 |
| C09 | M/39 | 3 | 1-69, 99.6 | + | 27 | +12 | 90/D | typical | +10.6 |
| C10 | M/30 | 4 | 3-09, 99.7 | + | 100 | 13q− | 80/D | prominent | +23.2 |
| C11 | F/67 | 2 | 3-30, 84.8 | − | 1 | 13q−, 17p− | 60/N | prominent | 101.9 |
| C12 | M/67 | 2 | 4-67, 94.9 | − | 3 | 13q− | 50/N | parafollicular | 29.4 |
| C13 | F/68 | 3 | 4-b, 100 | + | 97 | +12 | 80/D | diffuse | +10.5 |
| C14 | F/55 | 1 | 1-69, 100 | + | 2 | 13q− | na | typical | +35.6 |
| C16 | M/73 | 4 | 7-41, 93 | − | 1 | na | 85/D | na | +260 |
| C18 | M/56 | 2 | 3-74, 90.4 | − | 1 | normal | 40/N | na | +50.4 |
| C19 | F/73 | 1 | 3-30, 92.9 | − | 1 | 13q− | 30/N | na | 138 |
| C20 | M/73 | 1 | 4-39, 97.3 | − | 1 | 13q− | 30/N | na | 41.2 |
| C21 | F/74 | 1 | 4-04, 100 | + | 30 | 13q− | 10/D | na | 29.6 |
| C22 | M/74 | 2 | 1-18, 98.7 | + | > 30 | 13q− | 65/D+N | na | 121.2 |
| C23 | F/56 | 1 | 3-09, 98.6 | − | 68 | +12 | 75/D+N | na | 50.4 |
| C24 | M/52 | 2 | 4-61, 98.7 | + | 10 | 11q−, 17p− | na | typical | +3.9 |
| C25 | M/53 | 4 | 3-30, 99.7 | + | 72 | 13q− | 60/D+N | typical | +123 |
| C26 | F/57 | 2 | 3-09, 100 | + | 39 | +12 | 85/D | prominent | +21.7 |
IHC indicates immunohistochemistry; TTT, time to treatment (months from diagnosis to initiation of treatment); +, patients treated (treatment consisted of rituximab 375 mg/m2 on day 1 and fludarabine 25 mg/m2 on days 1-5 cycled every 4 weeks for 6 cycles; all others remained under continued observation without treatment); FISH, fluorescence in situ hybridization (only abnormalities detected in at least 10% of cells are shown); BM, bone marrow (% cellularity is given and the infiltration pattern is classified as N, nodular, or D, diffuse); LN-pc, pattern of proliferation centers in lymph node; and na, no sample available.